In August, Swing Therapeutics received FDA Breakthrough Device designation for its smartphone-based fibromyalgia management digital therapeutic. Now, the company has raised its $10.3 million Series A round to support a new clinical trial aimed at a possible FDA De Novo.
The startup's CEO, Mike Rosenbluth, sat down with MobiHealthNews to discuss why Swing's first product is focused on fibromyalgia...
Digital therapeutics startup Swing Therapeutics wrapped up a $10.3 million Series A funding round led by Jazz Venture Partners.
Other participants in the raise include Alumni Ventures, AME Cloud Ventures, Asahi Kasei Corporate Ventures, Gaingels, Kicker Ventures, Mana Ventures and Metrodora Ventures. Swing Therapeutics was founded in 2019 and launched with $9 million in seed funding.
WHAT THEY...
Digital therapeutics (DTx) startup Swing Therapeutics has been granted FDA Breakthrough Device Designation for its smartphone-administered fibromyalgia management program.
The FDA’s Breakthrough Devices Program gives medical device manufacturers an expedited regulatory review process while offering them the chance to coordinate with the agency throughout. It intends to speed up the time it takes...
